View Post

Aridhia announces expansion as it unveils digital platform in major Netherlands university medical centre

A Scottish clinical and translational informatics company has announced it is part of a consortium selected to deliver a digital research environment based on its AnalytiXagility informatics platform to one of the Netherland’s most prestigious university medical centres, with the aim of facilitating biomedical research on an unprecedented scale. The consortium, incorporating Aridhia, ICT service provider Vancis, and clinical datasets …

View Post

NIH funds biobank to support Precision Medicine Initiative Cohort Program

As part of President Obama’s Precision Medicine Initiative (PMI), the National Institutes of Health will award $142 million over five years to the Mayo Clinic, Rochester, Minnesota, to establish the world’s largest research-cohort biobank for the PMI Cohort Program, a longitudinal research study which aims to enroll 1 million or more U.S. participants to advance precision medicine. The award will …

View Post

HudsonAlpha Foundation establishes neurological disease research fund

Huntsville, Ala. — The HudsonAlpha Foundation has established the Memory and Mobility (M&M) Fund for neurological disease research. The M&M fund will support HudsonAlpha Institute for Biotechnology’s current and future neurological disease research. The first project will be to sequence the genomes of 1,500 patients with Alzheimer and Alzheimer-related dementia. “We have an unprecedented opportunity to access this data set …

View Post

Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund

Financing to expand the Second Genome Microbiome Discovery Platform and accelerate the clinical development of pipeline programs  South San Francisco, Calif., April 20, 2016 – Second Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, today announced that it has closed an oversubscribed Series B investment round with $42.6 million in financing. The round was co-led …

View Post

Dr Belinda Quinn appointed as Chief Executive Officer of the Precision Medicine Catapult

19 April 2016, Cambridge, UK – The Precision Medicine Catapult, the UK’s innovation centre for precision medicine, announces today it has appointed Dr Belinda Quinn as its new Chief Executive Officer. Belinda has been working as Chief Clinical Officer of the Precision Medicine Catapult over the past six months, formulating and landscaping Precision Medicine opportunities across the UK. She has …